Poor
Needs Revision
Patient Risk:
High
Summary
Most statements describe systemic/cytologic dosing management and symptom-based adverse effects that are not supported by the provided VECTICAL (calcitriol) Ointment label excerpts (which are topical-only and focus on application twice daily, dosing site restrictions, and hypercalcemia monitoring guidance). Several claims appear to mix content relevant to systemic calcitriol with topical VECTICAL labeling.
Category Scores
Accurate Statements
Calcitriol doses vary by the condition being treated.
Not supported by the provided label excerpts (which specify plaque psoriasis indication and fixed application frequency/dosing limits, not condition-specific systemic titration).
Too much calcitriol can raise blood calcium (hypercalcemia).
Supported in Section 5.1: hypercalcemia observed; treatment discontinued if calcium metabolism parameters aberrant until normalized.
If calcium is high, calcitriol dose reduction or temporary holding may be needed.
Partially supported in Section 5.1: if aberrations in calcium metabolism parameters occur, treatment should be discontinued until parameters normalize. (Label does not explicitly state 'dose reduction'; it states discontinuation until normalization.)
Unsupported Statements
Calcitriol dosing depends on a patient's kidney function.
Not supported by provided VECTICAL excerpts (label provided is topical psoriasis indication and topical dosing; no kidney-function–based dosing guidance included).
Calcitriol dosing depends on the patient's calcium level.
Not supported as a general dosing rule in the provided label excerpts; Section 5.1 addresses discontinuation if calcium metabolism aberrant, not dosing rules.
Calcitriol dosing is individualized.
No individualized dosing/titration framework is provided in the provided topical label excerpts.
Calcitriol dosing is adjusted based on serum calcium.
The provided excerpt specifies discontinuation when calcium metabolism parameters aberrant; it does not describe dose adjustment based on serum calcium.
Calcitriol dosing may be adjusted based on phosphorus.
Provided excerpt does not describe phosphorus-based dose adjustments.
In secondary hyperparathyroidism in chronic kidney disease (CKD), calcitriol therapy is typically started at low doses.
Not supported: the provided label excerpts indicate plaque psoriasis only (Section 1.1); no CKD/secondary hyperparathyroidism dosing guidance provided.
In secondary hyperparathyroidism in CKD, calcitriol dosing is titrated based on lab monitoring.
Not supported and appears unrelated to the provided VECTICAL plaque psoriasis label excerpts.
In hypocalcemia (including hypoparathyroidism), calcitriol doses are started conservatively.
Not supported: provided label excerpts do not include hypocalcemia/hypoparathyroidism indications or dosing guidance.
In hypocalcemia (including hypoparathyroidism), calcitriol doses are adjusted based on calcium levels.
Not supported: no such indication/dosing guidance provided.
Most calcitriol regimens are once daily.
Contradicted by provided label excerpt: VECTICAL should be applied twice daily (morning and evening).
Some patients may be prescribed different calcitriol schedules depending on the indication.
Provided label excerpt specifies apply twice daily; it does not describe indication-dependent schedule changes.
Some patients may be prescribed different calcitriol schedules depending on whether fine-tuning is needed.
Provided label excerpt does not describe schedule adjustments for 'fine-tuning'.
Dose changes for calcitriol are guided by repeat calcium testing.
Provided label excerpt (Section 5.1) describes discontinuation until parameters normalize; it does not specify that dose changes are guided by repeat calcium testing.
Clinicians typically monitor serum calcium for prevention or correction of low calcium.
Provided excerpt focuses on hypercalcemia risk and action when calcium metabolism parameters aberrant; it does not describe monitoring to prevent/correct low calcium.
Clinicians typically monitor serum calcium to avoid hypercalcemia.
The provided excerpt states hypercalcemia observed and to discontinue if parameters aberrant; it does not explicitly state a general 'typical monitoring' recommendation to avoid hypercalcemia.
Clinicians typically monitor phosphorus in some settings.
Provided label excerpt does not provide phosphorus monitoring recommendations.
Phosphorus monitoring may be especially used in CKD-related use.
Not supported: no CKD-related use guidance is provided in the excerpts.
Calcitriol doses are adjusted after lab results rather than on symptoms alone.
The provided excerpt does not describe any dosing adjustment scheme; only discontinuation if calcium metabolism parameters are aberrant.
Hypercalcemia due to excessive calcitriol may cause nausea.
The provided adverse reaction excerpt does not list nausea as an associated symptom.
Hypercalcemia due to excessive calcitriol may cause constipation.
The provided adverse reaction excerpt does not list constipation as an associated symptom.
Hypercalcemia due to excessive calcitriol may cause confusion.
The provided adverse reaction excerpt does not list confusion as an associated symptom.
Hypercalcemia due to excessive calcitriol may cause weakness.
The provided adverse reaction excerpt does not list weakness as an associated symptom.
Hypercalcemia due to excessive calcitriol may cause increased thirst.
The provided adverse reaction excerpt does not list increased thirst as an associated symptom.
Hypercalcemia due to excessive calcitriol may cause increased urination.
The provided adverse reaction excerpt does not list increased urination as an associated symptom.
Contradictions
High
AI Statement
Most calcitriol regimens are once daily.
Label Reference
Section 2: “Apply VECTICAL Ointment to affected areas twice daily, morning and evening.”
Important Omissions
Topical administration specifics: apply to affected areas twice daily (morning/evening), maximum weekly dose limits, and site restrictions (do not apply to eyes, lips, or facial skin; topical-only; not oral/ophthalmic/intravaginal).
Importance:
High
Indication scope: VECTICAL is indicated for topical treatment of mild to moderate plaque psoriasis in adults and pediatric patients 2 years and older.
Importance:
Moderate
Specific hypercalcemia management language from label: discontinue treatment until calcium metabolism parameters normalize; occlusive use may increase absorption.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Several claims incorrectly describe dosing/schedule (once daily), include dosing frameworks tied to systemic indications (CKD secondary hyperparathyroidism, hypocalcemia) not supported by the provided VECTICAL topical psoriasis label excerpts, and list symptom-based adverse effects not present in the provided label excerpts. These inaccuracies could lead to misuse of dosing/monitoring expectations inconsistent with the topical label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Major mismatch with VECTICAL topical labeling: regimen frequency and dosing/monitoring guidance are largely unsupported or inconsistent, with multiple statements referencing systemic indications not present in the provided label excerpts.
Suggested Improvement
Restrict statements to provided label-supported topical psoriasis use: apply twice daily with maximum weekly dose limits and site restrictions; include only label-supported hypercalcemia warning language (discontinue if calcium metabolism parameters aberrant; occlusive use may increase absorption) and avoid unlabelled symptom lists and systemic-indication dosing/titration claims.